This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gorny, M. K.
Right arrow Articles by Zolla-Pazner, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gorny, M. K.
Right arrow Articles by Zolla-Pazner, S.

 Previous Article  |  Next Article 

Journal of Virology, July 2006, p. 6865-6872, Vol. 80, No. 14
0022-538X/06/$08.00+0     doi:10.1128/JVI.02202-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Cross-Clade Neutralizing Activity of Human Anti-V3 Monoclonal Antibodies Derived from the Cells of Individuals Infected with Non-B Clades of Human Immunodeficiency Virus Type 1

Miroslaw K. Gorny,1 Constance Williams,1 Barbara Volsky,1 Kathy Revesz,4 Xiao-Hong Wang,4 Sherri Burda,1 Tetsuya Kimura,1 Frank A. J. Konings,2 Arthur Nádas,3 Christopher A. Anyangwe,5 Phillipe Nyambi,1,4 Chavdar Krachmarov,6 Abraham Pinter,6 and Susan Zolla-Pazner1,4*

Departments of Pathology,1 Microbiology,2 Institute of Environmental Medicine, New York University School of Medicine, New York, New York 10016,3 Research Enhancement Award Program, Veterans Affairs New York Harbor Healthcare System, New York, New York 10010,4 Alpha Royal Clinic, Bamenda, Cameroon,5 Public Health Research Institute, Newark, New Jersey 071036

Received 19 October 2005/ Accepted 28 February 2006

The majority of global human immunodeficiency virus infections are caused by viruses characterized by a GPGQ motif at the tip of the V3 loop. Characterization of anti-V3 monoclonal antibodies (MAbs) that neutralize isolates with the GPGQ V3 motif is an important step in designing vaccines that will induce such Abs. Consequently, seven human anti-V3 MAbs derived from the cells of individuals infected with non-B-subtype viruses (anti-V3non-B MAbs) were generated from the cells of individuals from Africa infected with circulating recombinant forms CRF02_AG, CRF09_cpx, and CRF13_cpx, each of which contains a subtype A env gene. Sequence analysis of plasma viruses revealed a GPGQ motif at the apex of the V3 loop from six of the seven subjects and a GPGR motif from one subject. The MAbs were selected with fusion proteins (FP) containing V392UG037.8 or V3JR-CSF from subtype A or B, respectively. In virus binding assays, five of the seven (71%) anti-V3non-B MAbs bound to V3-FPs from both subtype A and subtype B, while only four of the nine (44%) anti-V3B MAbs recognized both V3-FPs. Using two neutralization assays, both the anti-V3non-B and the anti-V3B MAbs neutralized subtype B viruses with similar activities, while the anti-V3non-B MAbs exhibited a tendency toward both increased potency and breadth of neutralization against non-B viruses compared to anti-V3B MAbs. Statistical significance was not achieved, due in large measure to the sizes of the MAb panels, but the overall pattern of data strongly suggests that viruses with the GPGQ motif at the tip of the V3 loop induce anti-V3 Abs with broader cross-neutralizing activity than do viruses with the GPGR motif.

* Corresponding author. Mailing address: Veterans Affairs Medical Center, 423 East 23rd St., Room 18124N, New York, NY 10010. Phone: (212) 263-6769. Fax: (212) 951-6321. E-mail: zollas01{at}med.nyu.edu.

Journal of Virology, July 2006, p. 6865-6872, Vol. 80, No. 14
0022-538X/06/$08.00+0     doi:10.1128/JVI.02202-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Wallace, A., Stamatatos, L. (2009). Introduction of Exogenous Epitopes in the Variable Regions of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein: Effect on Viral Infectivity and the Neutralization Phenotype. J. Virol. 83: 7883-7893 [Abstract] [Full Text]  
  • Davis, K. L., Bibollet-Ruche, F., Li, H., Decker, J. M., Kutsch, O., Morris, L., Salomon, A., Pinter, A., Hoxie, J. A., Hahn, B. H., Kwong, P. D., Shaw, G. M. (2009). Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma. J. Virol. 83: 1240-1259 [Abstract] [Full Text]  
  • Kraft, Z., Strouss, K., Sutton, W. F., Cleveland, B., Tso, F. Y., Polacino, P., Overbaugh, J., Hu, S.-L., Stamatatos, L. (2008). Characterization of Neutralizing Antibody Responses Elicited by Clade A Envelope Immunogens Derived from Early Transmitted Viruses. J. Virol. 82: 5912-5921 [Abstract] [Full Text]  
  • Patel, M. B., Hoffman, N. G., Swanstrom, R. (2008). Subtype-Specific Conformational Differences within the V3 Region of Subtype B and Subtype C Human Immunodeficiency Virus Type 1 Env Proteins. J. Virol. 82: 903-916 [Abstract] [Full Text]  
  • Nishiyama, Y., Mitsuda, Y., Taguchi, H., Planque, S., Salas, M., Hanson, C. V., Paul, S. (2007). Towards Covalent Vaccination: IMPROVED POLYCLONAL HIV NEUTRALIZING ANTIBODY RESPONSE INDUCED BY AN ELECTROPHILIC gp120 V3 PEPTIDE ANALOG. J. Biol. Chem. 282: 31250-31256 [Abstract] [Full Text]  
  • Krachmarov, C. P., Honnen, W. J., Kayman, S. C., Gorny, M. K., Zolla-Pazner, S., Pinter, A. (2006). Factors Determining the Breadth and Potency of Neutralization by V3-Specific Human Monoclonal Antibodies Derived from Subjects Infected with Clade A or Clade B Strains of Human Immunodeficiency Virus Type 1. J. Virol. 80: 7127-7135 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»